All questionsSpecific populations: Vabysmo (faricimab-svoa), all indications7 questions · 1 sourcePregnancy and breastfeedingCan Vabysmo be used during pregnancy?“There are no adequate and well-controlled studies of VABYSMO administration in pregnant women. Administration of VABYSMO to pregnant monkeys throughout the period of organogenesis resulted in an increased incidence of abortions at intravenous (IV) doses 158 times the human exposure (based on Cmax) of the maximum recommended human dose [see Animal Data]. Based on the mechanism of action of VEGF and Ang-2 inhibitors, there is a potential risk to female reproductive capacity, and to embryo-fetal development. VABYSMO should not be used during pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus.” (opens the source at this quote in a new tab)CopyFlagCan Vabysmo be used while breastfeeding?“There is no information regarding the presence of faricimab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Many drugs are transferred in human milk with the potential for absorption and adverse reactions in the breastfed child. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VABYSMO and any potential adverse effects on the breastfed child from VABYSMO.” (opens the source at this quote in a new tab)CopyFlagHow long is contraception needed after the last Vabysmo dose?“Females of reproductive potential are advised to use effective contraception prior to the initial dose, during treatment and for at least 3 months following the last dose of VABYSMO.” (opens the source at this quote in a new tab)CopyFlagSpecific populationsDoes Vabysmo affect fertility?“No studies on the effects of faricimab on human fertility have been conducted and it is not known whether faricimab can affect reproduction capacity. Based on the mechanism of action, treatment with VABYSMO may pose a risk to reproductive capacity.” (opens the source at this quote in a new tab)CopyFlagIs Vabysmo safe for adults 65 and older?“In the six clinical studies, approximately 58% (1,496/2,571) of patients randomized to treatment with VABYSMO were ≥ 65 years of age. No significant differences in efficacy or safety of faricimab were seen with increasing age in these studies. No dose adjustment is required in patients 65 years and above.” (opens the source at this quote in a new tab)CopyFlagDoes Vabysmo need a dose adjustment for kidney or liver problems?“The systemic pharmacokinetics of faricimab were not influenced by gender, race, or mild to severe renal impairment (i.e., estimated normalized creatinine clearance by Cockroft-Gault equation: 15 to 89 mL/min/1.73 m2). The effect of severe renal impairment or any degree of hepatic impairment on the pharmacokinetics of VABYSMO is unknown. No special dosage modification is required for any of the populations that have been studied (e.g., elderly, gender, race).” (opens the source at this quote in a new tab)CopyFlagPediatric useIs Vabysmo safe and effective for children?“The safety and efficacy of VABYSMO in pediatric patients have not been established.” (opens the source at this quote in a new tab)CopyFlag